Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in <i>FLT3</I>-mutated acute myeloid leukemia

• Julia S. Lee,
• Charlotte B. Wagner,
• Stacy Prelewicz,
• Heena P. Kurish,
• Robert Walchack,
• Danielle A. Cenin,
• Seema Patel,
• Mimi Lo,
• Danielle Schlafer,
• Belinda K.T. Li,
• R. Donald Harvey III,
• Bestis Wasef,
• Jian Ying,
• Tibor Kovacsovics

Affiliations

Julia S. Lee

Department of Pharmacy, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Charlotte B. Wagner

Department of Pharmacy, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Stacy Prelewicz

Department of Pharmacy, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Heena P. Kurish

Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH

Robert Walchack

Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH

Danielle A. Cenin

Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH

Seema Patel

Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH

Mimi Lo

Department of Pharmaceutical Services, University of California San Francisco, San Francisco, CA

Danielle Schlafer

Department of Hematology and Medical Oncology, Winship Cancer Institute/Emory Healthcare, Atlanta, GA

Belinda K.T. Li

Department of Hematology and Medical Oncology, Winship Cancer Institute/Emory Healthcare, Atlanta, GA

R. Donald Harvey III

Department of Hematology and Medical Oncology, Winship Cancer Institute/Emory Healthcare, Atlanta, GA

Bestis Wasef

Department of Pharmacy, Oregon Health and Science University Hospital, Portland, OR

Jian Ying

Division of Public Health, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Tibor Kovacsovics

Division of Hematology, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT